S
688163
vs
S
Shanghai Composite
Over the past 12 months, Shanghai Serum Bio-Technology Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +46% compared to the Shanghai Composite's +25% growth.
Stocks Performance
688163 vs Shanghai Composite
Performance Gap
688163 vs Shanghai Composite
Performance By Year
688163 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shanghai Serum Bio-Technology Co Ltd
Glance View
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, and sale of anti-toxin and anti-serum products. The company is headquartered in Shanghai, Shanghai and currently employs 308 full-time employees. The company went IPO on 2022-03-11. The firm is mainly engaged in the research, development, manufacturing and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety. The firm's main products include anti-pit viper venom, anti-five-step snake venom, anti-bungi venom, anti-cobra venom, equine immunoglobulin and anti-rabies serum. The firm's products are mainly used for emergency snakebite treatment. The firm mainly conducts its businesses in the domestic market.
